Bausch Health’s Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant MD Touch Laser in Canada

• LAVAL, QUEBEC – Bausch Health Companies Inc., a diversified global pharmaceutical company, and Solta Medical, a global leader in aesthetic medicine, announced the launch of the Clear + Brilliant ^MD Touch laser in Canada. The device was approved by Health Canada on May 20, 2025, a significant milestone for the company as demand for non-invasive skin rejuvenation treatments continues to grow in the country. Canadian physicians now have access to one of the most advanced dual-wavelength laser technologies on the market, facilitating access to customizable treatments that align with the growing preference among Canadians for effective and affordable skin rejuvenation options.

“Solta’s international reach remains strong. With its extensive range of well-established products, Solta is meeting the growing demand for high-quality aesthetic solutions,” said Thomas J. Appio, CEO of Bausch Health. “Canada is an important part of this growth, as there is a strong and sustained interest in the aesthetics market across the country.”

Inspired by the highly successful Clear + Brilliant Touch system launched in the United States in 2021, the device’s innovative design allows for the use of two handpieces, each emitting a distinct wavelength, thus providing comprehensive treatments that leave skin looking smoother, brighter, and younger. The system is suitable for all skin types and age groups and can be used year-round (at the discretion of the treating physician). Its key advantages include ease of use, minimal downtime, and a gentle yet effective approach.

“Expanding access to the Clear + Brilliant Touch system by introducing it to the Canadian market marks a significant step forward for Solta Medical and its mission to globally expand its innovative skin health portfolio,” said Jiny Kim, Senior Vice President at Solta Medical, Bausch Health. “This launch further solidifies Solta’s leadership position in serving healthcare providers and patients by providing safe, effective, and customizable technologies.”

^{Indications for Clear + Brilliant MD} Touch laser treatment (Canada)

^{The Clear + Brilliant MD} Touch system is indicated for dermatological procedures requiring soft tissue coagulation and general skin resurfacing. The system includes two fractional laser handpieces, each with its own specific indication:

Handpiece at 1440 nm

• Indicated for the treatment and improvement of the appearance of the following skin characteristics:
  • Wrinkles
  • Dyschromia
  • Pigmentation
  • Skin texture
  • Pore ​​size

1927 nm handpiece

• Indicated for the treatment and improvement of the appearance of the following skin characteristics:
  • Wrinkles
  • Dyschromia
  • Pigmentation
  • Skin texture
  • Skin permeability
  • Pore ​​size

About the Clear + Brilliant ^MD Touch laser

The Clear + Brilliant ^MD Touch laser from Solta Medical is now available in Canada, joining the existing Clear + Brilliant ^MD line . Backed by robust evidence from over 15 clinical studies, the Clear + Brilliant ^MD platform is a fractional laser technology that produces both structural and functional changes in the skin. In Canada, this type of treatment could address certain signs of aging, help maintain youthful-looking skin, and improve overall skin appearance.

Since 2011, the Clear + Brilliant ^MD platform has helped define the horizon of laser treatments in international markets.

To learn more about the Clear + Brilliant ^MD Touch laser and for important safety information, visit ca.clearandbrilliant.com/fr-CA/hcp .

About Bausch Health

Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) is a diversified global pharmaceutical company dedicated to improving people’s lives and driven by an unwavering commitment to improving healthcare outcomes. We develop, manufacture, and market a broad range of pharmaceutical products, primarily in the therapeutic areas of gastroenterology, hepatology, neuroscience, dermatology, dentistry, and aesthetics, as well as eye health globally through our majority stake in Bausch + Lomb. We aspire to be a globally integrated healthcare company that is trusted and valued by patients, healthcare professionals, employees, and investors. Our aesthetics business, Solta Medical, is a global leader in aesthetic medicine, committed to creating and supporting trusted aesthetic brands that deliver value to both customers and patients. You can find more information about Solta Medical at www.solta.com . To learn more about Bausch Health, visit www.bauschhealth.com ; you can also connect with us via LinkedIn.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of applicable securities laws, including the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identified by the use of future or conditional tenses, or by verbs such as “anticipate,” “hope,” “expect,” “intend,” “forecast,” “believe,” “subject to,” or variations thereof. These statements are not historical facts or guarantees of future performance; they are based on management’s current expectations and beliefs and are subject to other risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that depend more broadly on Bausch Health’s overall business, including those described in greater detail in Bausch Health’s most recent annual and quarterly reports and Bausch Health’s detailed reports or other documents regularly filed with the U.S. Securities and Exchange Commission or Canadian securities regulators, factors which are incorporated herein by reference. Readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof. The company undertakes no obligation to update these forward-looking statements to reflect events, circumstances, or information after the date of this press release or to reflect actual results, except as required by law.

Original source here.